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Minimum inhibitory concentrationBackground and objectives: Bacterial DNA topoisomerases are unique in maintaining the
DNA topology for cell viability. Mycobacterium tuberculosis (MTB) DNA gyrase, a sole type II
topoisomerase has a larger scope as a target for developing novel therapeutics. In this
study, an effort was made towards the design and synthesis of benzothiazinone-piperazine
hybrid analogues to obtain the possibility of it to lead development through the molecular
hybridization technique.
Methods: A five-step scheme was followed to obtain a series of 36 benzothiazinone-piper-
azine derivatives and to evaluate them for MTB DNA gyrase inhibition, antimycobacterial
and cytotoxicity studies.
Results: Compound N-(4-chlorophenyl)-4-(6-nitro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)piper-
azine-1-carbothioamide (18) showed greater inhibitory potential with an IC50 of
0.51 ± 0.16 lM in the DNA supercoiling assay of MTB with a moderate anti-tubercular activ-
ity of 4.41 lM. The compound even passed the safety profile of eukaryotic cell cytotoxicity
with a 1.81% inhibition in the RAW 264.7 cell line at 100 lM concentration.
Conclusions: This study describes the discovery of benzothiazinone as gyrase inhibitors
with potent MTB MIC and inhibitory profiles of the gyrase enzyme with less cytotoxic
effect. Furthermore, it is believed that this class of compounds has the potential to be fur-
ther developed as an anti-TB drug candidate.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB) is a major threat to mankind and claims
approximately 1.5 million lives each year according to the
World Health Organization (WHO) [1]. Statistics report that
one-third of the global population is infected by the latent
bacilli Mycobacterium tuberculosis (MTB). Moreover, in 2012globally an estimated half a million people fell ill with mul-
tidrug-resistant tuberculosis (MDR-TB) [2]. Furthermore, the
first-line TB drugs currently in use are at least 40 years old
with an increase in drug-resistant strains of MTB. Similarly,
the second-line drugs used mainly for the treatment of mul-
tidrug-resistant and extensively drug-resistant (XDR) TB
induce serious side effects according to WHO [3]; there is an
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newer combination regimens for treating MDR and XDR-TB.
Presently, bedaquiline [4] is the only approved drug by the
FDA, whereas delamanid [5], SQ109 [6], oxazolidinones [7]
and fluoroquinolones [8] are still in the clinical development
stage. Hence, there is an urgent need for discovery of novel
antimycobacterial agents to replenish the TB pipeline drugs.
DNA topoisomerases maintain the DNA topology during
replication, transcription and recombination. Among many
topoisomerases, DNA gyrase is the sole topoisomerase II
enzyme present in MTB [9]. It mainly consists of GyrA and
GyrB domains, in the holoenzyme complex as A2B2. While
the GyrA subunit mainly interacts with the DNA and pos-
sesses the active-site tyrosine responsible for DNA cleavage
and re-ligation, the GyrB subunit helps in the ATP hydrolysis,
thus acting as a catalytic site for the enzyme [10,11]. This
enzyme is absent in the eukaryotic organisms, though a less
homologous enzyme does exist; thus, it seems to be an attrac-
tive target for developing novel drugs against TB. Though flu-
oroquinolones have been efficient bactericidal antimicrobials,
they are losing their potency due to the resistance being
developed rapidly. Hence, in the present study, a drug discov-
ery program was initiated through molecular hybridization
targeting DNA gyrase of MTB; herein this study describes
the design and development of benzothiazinone hybrids as
novel compounds using the chemical structure of the pre-
viously reported antitubercular benzothiazinone bearing (left
hand side) derivative PBTZ169 [12,13] and the MTB DNA gyr-
ase inhibitor bearing aryl (thio) urea right hand side chain
[14,15].Materials and methods
General
All commercially available chemicals and solvents were used
without further purification. TLC experiments were per-
formed on alumina-backed silica gel 40 F254 plates (Merck,
Darmstadt, Germany). Homogeneity of the compounds was
monitored by thin layer chromatography (TLC) on silica gel
40 F254 coated on aluminium plates, visualized by UV light
and KMnO4 treatment. All
1H and 13C NMR spectra were
recorded on a Bruker AM-300 (300.12 MHz, 75.12 MHz) NMR
spectrometer, BrukerBioSpin Corp, Germany. Chemical shifts
were reported in ppm (d) with reference to the internal stan-
dard TMS. The signals were designated as follows: s, singlet;
d, doublet; t, triplet; m, multiplet. Molecular weights of the
synthesized compounds were checked by LCMS 6100B series
Agilent Technology. Elemental analyses were carried out on
an automatic Flash EA 1112 Series, CHN Analyzer (Thermo).General procedure for the synthesis of 5-substituted-2-
chlorbenzamides (2a–c)
To a stirred solution of the corresponding acid (1a–c) (1 mmol)
in dichloromethane (15 ml) at 10 C was added oxalyl chlo-
ride (2.5 mmol). The solution was refluxed for about 6 h
(monitored by TLC and LCMS for completion), and solvent
evaporated under reduced pressure. The residue was furtherdiluted with acetonitrile (30 ml), cooled to 20 C and added
ammonium hydroxide solution drop wise and allowed to stir
for 30 min. The resulting solid was filtered out to afford the
corresponding amide (2a–c) in good yield.
2-Chloro-5-nitrobenzamide (2a)
The compound was synthesized according to the general pro-
cedure using 2-chloro-5-nitrobenzoic acid (1a) (5.0 g,
0.02 mmol), oxalyl chloride (5.3 ml, 0.05 mmol) and aqueous
ammonium hydroxide (50 ml) to afford 2a (3.9 g, 78.4%) as yel-
low solid. M.p: 185–187 C. 1H NMR (DMSO-d6): dH 8.28–7.83 (m,
3H), 7.52 (b, 1H). 13C NMR (DMSO-d6): dC 168.2, 146.2, 140.3,
130.7, 128.5, 122.1. ESI-MS m/z 201 (M+H)+. Anal. calcd. for
C7H5ClN2O3: C, 41.92; H, 2.51; N, 13.97; Found: C, 41.89; H,
2.54; N, 13.99.
2-Chloro-5-(trifluoromethyl)benzamide (2b)
The compound was synthesized according to the general pro-
cedure using 2-chloro-5-(trifluoromethyl)benzoic acid (1b)
(4.0 g, 0.01 mmol), oxalyl chloride (3.8 ml, 0.04 mmol) and
aqueous ammonium hydroxide (40 ml) to afford 2b (1.84 g,
46.2%) as white solid. M.p: 176–178 C. 1H NMR (DMSO-d6): dH
8.02–7.64 (m, 3H), 7.54 (b, 1H). 13C NMR (DMSO-d6): dC 168.4,
137.7, 132.3, 129.7, 129.5, 128.1, 125.3. 123.5. ESI-MS m/z 224
(M+H)+. Anal. calcd. for C8H5ClF3NO: C, 42.98; H, 2.25; N,
6.26; Found: C, 41.89; H, 2.54; N, 13.99.
2,5-Dichlorobenzamide (2c)
The compound was synthesized according to the general pro-
cedure using 2,5-dichlorobenzoic acid (1c) (4.0 g, 0.02 mmol),
oxalyl chloride (4.5 ml, 0.05 mmol) and aqueous ammonium
hydroxide (40 ml) to afford 2c (2.12 g, 53.4%) as white solid.
M.p: 181–183 C. 1H NMR (DMSO-d6): dH 7.89–7.63 (m, 3H),
7.52 (b, 1H). 13C NMR (DMSO-d6): dC 168.6, 133.5, 132.3, 132.1,
129.4, 128.6. ESI-MS m/z 192 (M+H)+. Anal. calcd. for
C7H5Cl2NO: C, 44.24; H, 2.65; N, 7.37; Found: C, 44.26; H, 2.64;
N, 7.39.
General procedure for the synthesis of 5-substituted-2-
(methylthio)-4H-benzo[e][1,3]thiazin-4-one (3a–c)
To a stirred solution of the corresponding benzamide (2a–c)
(1 mmol) in DMSO (15 ml) at 10 C was added carbon disul-
phide (3 mmol), sodium hydroxide (2 mmol), and the mixture
was allowed to stand for 15 min. Subsequently, methyl iodide
(1.2 mmol) was added. The reaction mixture was allowed to
stand for another 30 min, and 50 ml of water was added.
The resulting white solid separated by filtration to afford
the corresponding benzothiazinone (3a–c) in good yield.
2-(Methylthio)-6-nitro-4H-benzo[e][1,3]thiazin-4-one (3a)
The compound was synthesized according to the general pro-
cedure using 2-chloro-5-nitrobenzamide (2a) (2.0 g,
9.97 mmol), carbon disulphide (1.8 ml, 29.9 mmol), sodium
hydroxide (0.79 g, 19.9 mmol) and methyl iodide (0.73 ml,
11.9 mmol) to afford 3a (1.82 g, 71.9%) as yellow solid. M.p:
106 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 1 0 4 –1 1 5211–213 C. 1H NMR (DMSO-d6): dH 8.36–7.82 (m, 3H), 2.72 (s,
3H). 13C NMR (DMSO-d6): dC 167.6, 162.4, 145.3, 143.6, 138.4,
130.5, 128.4, 123.6, 14.2. ESI-MS m/z 255 (M+H)+. Anal. calcd.
for C9H6N2O3S2: C, 42.51; H, 2.38; N, 11.02; Found: C, 42.54; H,
2.36; N, 11.05.
2-(Methylthio)-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-
one (3b)
The compound was synthesized according to the general pro-
cedure using 2-chloro-5-(trifluoromethyl)benzamide (2b)
(1.5 g, 6.71 mmol), carbon disulphide (1.2 ml, 20.1 mmol),
sodium hydroxide (0.53 g, 13.4 mmol) and methyl iodide
(0.49 ml, 8.1 mmol) to afford 3b (1.63 g, 88.1%) as white solid.
M.p: 208–210 C. 1H NMR (DMSO-d6): dH 8.35–7.78 (m, 3H),
2.72 (s, 3H). 13C NMR (DMSO-d6): dC 167.4, 162.5, 140.3, 137.6,
131.4, 130.6, 128.4, 126.6, 123.5, 14.3. ESI-MS m/z 278 (M+H)+.
Anal. calcd. for C10H6F3NOS2: C, 43.32; H, 2.18; N, 5.05;
Found: C, 43.33; H, 2.16; N, 5.03.
6-Chloro-2-(methylthio)-4H-benzo[e][1,3]thiazin-4-one (3c)
The compound was synthesized according to the general pro-
cedure using 2,5-dichlorobenzamide (2c) (2.0 g, 10.52 mmol),
carbon disulphide (1.9 ml, 31. mmol), sodium hydroxide
(0.84 g, 21.1 mmol) and methyl iodide (0.78 ml, 12.6 mmol) to
afford 3c (1.57 g, 61.3%) as white solid. M.p: 219–221 C. 1H
NMR (DMSO-d6): dH 8.36–7.74 (m, 3H), 2.72 (s, 3H).
13C NMR
(DMSO-d6): dC 167.8, 162.5, 138.3, 135.6, 134.4, 131.6, 131.4,
130.6, 14.3. ESI-MS m/z 244 (M+H)+. Anal. calcd. for
C9H6ClNOS2: C, 44.35; H, 2.48; N, 5.75; Found: C, 44.33; H,
2.46; N, 5.73.General procedure for the synthesis of 6-substitutedo-2-
(piperazin-1-yl)-4H-benzo[e][1,3]thiazin-4-ones (4a–c)
To a stirred solution of the corresponding benzothiazinone
(3a) (1 mmol) in ethanol (15 ml) at room temperature was
added 1-Boc-piperazine (1 mmol). The solution was refluxed
for about 12 h (monitored by TLC and LCMS for completion),
and solvent evaporated under reduced pressure. The residue
was further diluted with water (30 ml) and ethyl acetate
(50 ml) and the layers were separated. The organic layer was
dried over anhydrous sodium sulphate and evaporated under
reduced pressure. The residue was purified by silica gel col-
umn chromatography using hexane: ethyl acetate as eluent
to give the corresponding N-boc protected piperazine ben-
zothiazinones in good yield, which was taken in dichloro-
methane (60 ml) and was cooled to 0 C and was added
trifluoroacetic acid (8 ml) and stirred the reaction at room
temperature for 1 h. After completion of the reaction by
TLC, the reaction mixture was cooled to 0 C and basified to
pH 8.0 using saturated aqueous NaHCO3 solution. The
organic layer was separated, washed with water (2 · 20 ml)
and brine (1 · 20 ml) and dried over anhydrous sodium sul-
phate. The organic layer was concentrated under vacuum
afforded the free amine as pale brown oil. The crude material
was used for final reactions without purification.6-Nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thiazin-4-one (4a)
The compound was synthesized according to the general pro-
cedure using 2-(methylthio)-6-nitro-4H-benzo[e][1,3]thiazin-
4-one (3a) (1.8 g, 7.08 mmol), 1-Boc-piperazine (1.31 g,
7.08 mmol) and trifluoroacetic acid (2 ml) to afford 4a (1.33 g,
64.5%) as yellow solid. M.p: 208–210 C. 1H NMR (DMSO-d6):
dH 8.33–7.24 (m, 3H), 5.25 (b, 2H), 3.12–1.88 (m, 9H).
13C NMR
(DMSO-d6): dC 167.5, 159.3, 145.6, 143.6, 138.4, 130.3, 128.4,
123.6, 46.7, 41.5 (2C), 32.2 (2C). ESI-MS m/z 307 (M+H)+. Anal.
calcd. for C13H14N4O3S: C, 50.97; H, 4.61; N, 18.29; Found: C,
50.96; H, 4.65; N, 18.31.2-(Piperazin-1-yl)-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-4-one (4b)
The compound was synthesized according to the general pro-
cedure using 2-(methylthio)-6-(trifluoromethyl)-4H-benzo[e]
[1,3]thiazin-4-one (3b) (1.6 g, 5.77 mmol), 1-Boc-piperazine
(1.07 g, 5.77 mmol) and trifluoroacetic acid (2 ml) to afford 4b
(1.28 g, 70.7%) as white solid. M.p: 221–223 C. 1H NMR
(DMSO-d6): dH 8.32–7.27 (m, 3H), 5.26 (b, 2H), 3.14–1.85 (m,
9H). 13C NMR (DMSO-d6): dC 167.2, 159.4, 140.7, 137.6, 131.4,
130.3, 128.5, 126.8, 123.3, 46.7, 41.4 (2C), 32.5 (2C). ESI-MS m/z
330 (M+H)+. Anal. calcd. for C14H14F3N3OS: C, 51.06; H, 4.28;
N, 12.76; Found: C, 51.08; H, 4.27; N, 12.73.
6-Chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thiazin-4-one
(4c)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(methylthio)-4H-benzo[e][1,3]thiazin-
4-one (3c) (1.5 g, 6.15 mmol), 1-Boc-piperazine (1.14 g,
6.15 mmol) and trifluoroacetic acid (2 ml) to afford 4c (1.44 g,
83.2%) as white solid. M.p: 217–219 C. 1H NMR (DMSO-d6): dH
8.33–7.28 (m, 3H), 5.24 (b, 2H), 3.12–1.88 (m, 9H). 13C NMR
(DMSO-d6): dC 167.4, 159.5, 138.6, 135.1, 134.4, 131.3, 131.1,
130.2, 46.8, 41.4 (2C), 32.2 (2C). ESI-MS m/z 296 (M+H)+. Anal.
calcd. for C13H14ClN3OS: C, 52.79; H, 4.77; N, 14.21; Found: C,
52.82; H, 4.76; N, 14.25.
General procedure for the synthesis of 4-(6-substituted-4-oxo-
4H-benzo[e][1,3]thiazin-2-yl)-N-arylpiperazine-1-
carboxamide derivatives (5–16)
To a cooled solution of 6-substituted-2-(piperazin-1-yl)-4H-
benzo[e][1,3]thiazin-4-one (1 mmol) in anhydrous DCM
(2 ml) was added corresponding isocyanate (1 mmol), triethy-
lamine (1 mmol) and stirred the reaction mixture at room
temperature for 12 h (monitored by TLC and LCMS for com-
pletion), and solvent evaporated under reduced pressure.
The residue was further diluted with water (30 ml) and ethyl
acetate (50 ml) and the layers were separated. The organic
layer was dried over anhydrous sodium sulphate and evapo-
rated under reduced pressure. The residue was purified by sil-
ica gel column chromatography using hexane: ethyl acetate
as eluent to give the corresponding urea derivative (5–16) in
good yield.
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phenylpiperazine-1-carboxamide (5)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol) and Phenyl isocyanate
(0.04 g, 0.34 mmol) to afford 5 (0.06 g, 46.18%) as yellow solid.
M.p: 211–213 C. 1H NMR (DMSO-d6): dH 10.59 (b, 1H), 8.56–7.48
(m, 8H), 3.12–1.88 (m, 8H). 13C NMR (DMSO-d6): dC 167.4, 159.2,
155.7, 145.3, 143.6, 139.1, 138.2, 130.2, 128.7 (3C), 128.1, 123.5,
121.5 (2C), 51.6 (2C), 48.5 (2C). ESI-MS m/z 412 (M+H)+. Anal.
calcd. for C19H17N5O4S: C, 55.47; H, 4.16; N, 17.02; Found: C,
55.44; H, 4.52.15; N, 17.06.
N-(4-Chlorophenyl)-4-(6-nitro-4-oxo-4H-
benzo[e][1,3]thiazin-2-yl)piperazine-1-carboxamide (6)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol) and 4-chlorophenyl
isocyanate (0.05 g, 0.34 mmol) to afford 6 (0.08 g, 53.10%) as
yellow solid. M.p: 203–205 C. 1H NMR (DMSO-d6): dH 10.58 (b,
1H), 8.54–7.43 (m, 7H), 3.12–1.88 (m, 8H). 13C NMR (DMSO-d6):
dC 167.5, 159.3, 155.5, 145.7, 143.4, 138.2, 137.2, 133.7, 130.1,
129.5 (2C), 128.5, 123.7, 120.5 (2C), 51.6 (2C), 48.4 (2C). ESI-MS
m/z 446 (M+H)+. Anal. calcd. for C19H16ClN5O4S: C, 51.18; H,
3.62; N, 15.71; Found: C, 51.21; H, 3.64; N, 15.69.
4-(6-Nitro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(p-
tolyl)piperazine-1-carboxamide (7)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol) and p-tolyl isocyanate
(0.04 g, 0.34 mmol) to afford 7 (0.05 g, 35.73%) as yellow solid.
M.p: 208–210 C. 1H NMR (DMSO-d6): dH 10.56 (b, 1H), 8.57–7.46
(m, 7H), 3.11–1.87 (m, 8H), 2.36 (s, 3H). 13C NMR (DMSO-d6): dC
167.4, 159.2, 155.7, 145.3, 143.2, 138.6, 136.8, 136.3, 130.5, 129.5
(2C), 128.8, 123.6, 121.3 (2C), 51.3 (2C), 48.4 (2C), 21.2. ESI-MSm/
z 426 (M+H)+. Anal. calcd. for C20H19N5O4S: C, 56.46; H, 4.50; N,
16.46; Found: C, 56.43; H, 4.54; N, 16.43.
4-(6-Nitro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(4-
nitrophenyl)piperazine-1-carboxamide (8)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol) and 4-nitrophenyl
isocyanate (0.05 g, 0.34 mmol) to afford 8 (0.02 g, 14.73%) as
yellow solid. M.p: 226–228 C. 1H NMR (DMSO-d6): dH 10.56 (b,
1H), 8.58–7.48 (m, 7H), 3.14–1.89 (m, 8H). 13C NMR (DMSO-d6):
dC 167.6, 159.4, 154.1, 145.7, 145.2, 143.6, 143.4, 138.5, 130.9,
128.7, 124.2 (2C), 123.6, 119.5 (2C), 51.5, 48.6 (2C). ESI-MS m/z
457 (M+H)+. Anal. calcd. for C19H16N6O6S: C, 50.00; H, 3.53; N,
18.41; Found: C, 50.02; H, 3.51; N, 18.38.
4-(4-Oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-yl)-
N-phenylpiperazine-carboxamide (9)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol) and phenyl
isocyanate (0.03 g, 0.31 mmol) to afford 9 (0.08 g, 62.39%) as
white solid. M.p: 213–215 C. 1H NMR (DMSO-d6): dH 10.52 (b,
1H), 8.51–7.40 (m, 8H), 3.12–1.84 (m, 8H). 13C NMR (DMSO-d6):
dC 167.7, 159.4, 155.6, 140.7, 139.4, 137.6, 131.3, 130.6, 128.7
(2C), 128.2, 126.1, 123.4, 121.5 (2C), 51.2 (2C), 48.4 (2C). ESI-MS
m/z 435 (M+H)+. Anal. calcd. for C20H17F3N4O2S: C, 55.29; H,
3.94; N, 12.90; Found: C, 55.26; H, 3.95; N, 12.88.
N-(4-Chlorophenyl)-4-(4-oxo-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-2-yl)piperazine-1-carboxamide (10)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol) and 4-
chlorophenyl isocyanate (0.04 g, 0.31 mmol) to afford 10
(0.05 g, 34.95%) as white solid. M.p: 211–213 C. 1H NMR
(DMSO-d6): dH 10.51 (b, 1H), 8.50–7.38 (m, 7H), 3.14–1.82 (m,
8H). 13C NMR (DMSO-d6): dC 167.4, 159.6, 155.7, 140.2, 137.7,
137.3, 133.2, 131.2, 130.4, 129.1 (2C), 128.5, 126.6, 123.6, 120.7
(2C), 51.5 (2C), 48.4 (2C). ESI-MS m/z 469 (M+H)+. Anal. calcd.
for C20H16ClF3N4O2S: C, 51.23; H, 3.44; N, 11.95; Found: C,
51.25; H, 3.45; N, 11.96.
4-(4-Oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-yl)-
N-(p-tolyl)piperazine-1-carboxamide (11)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol) and p-
tolylisocyanate (0.04 g, 0.31 mmol) to afford 11 (0.04 g,
32.33%) as white solid. M.p: 216–218 C. 1H NMR (DMSO-d6):
dH 10.54 (b, 1H), 8.51–7.41 (m, 7H), 3.13–1.83 (m, 8H), 2.38 (s,
3H). 13C NMR (DMSO-d6): dC 167.6, 159.5, 155.6, 140.7, 137.2,
136.6, 131.2, 130.2, 129.3 (2C), 128.3, 126.6, 123.6, 121.4 (2C),
51.2 (2C), 48.1 (2C), 21.3. ESI-MS m/z 449 (M+H)+. Anal. calcd.
for C21H19F3N4O2S: C, 56.24; H, 4.27; N, 12.49; Found: C, 56.28;
H, 4.24; N, 12.47.
N-(4-Nitrophenyl)-4-(4-oxo-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-2-yl)piperazine-1-carboxamide (12)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol) and 4-
nitrophenyl isocyanate (0.05 g, 0.31 mmol) to afford 12
(0.03 g, 25.64%) as white solid. M.p: 201–203 C. 1H NMR
(DMSO-d6): dH 10.55 (b, 1H), 8.55–7.46 (m, 7H), 3.15–1.85 (m,
8H). 13C NMR (DMSO-d6): dC 167.7, 159.2, 155.1, 145.8, 143.2,
140.6, 137.2, 131.3, 130.2, 128.4, 126.3, 124.4 (2C), 123.6, 119.6
(2C), 51.5 (2C), 48.8 (2C). ESI-MS m/z 480 (M+H)+. Anal. calcd.
for C20H16F3N5O4S: C, 50.10; H, 3.36; N, 14.61; Found: C, 50.13;
H, 3.34; N, 14.58.
4-(6-Chloro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-
phenylpiperazine-1-carboxamide (13)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol) and phenyl isocyanate (0.04 g,
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217–219 C. 1H NMR (DMSO-d6): dH 10.50 (b, 1H), 8.54–7.39 (m,
8H), 3.16–1.89 (m, 8H). 13C NMR (DMSO-d6): dC 167.4, 159.5,
155.2, 139.8, 138.2, 135.6, 134.2, 131.3, 131.2, 130.4, 128.7 (2C),
128.4, 121.6 (2C), 51.6 (2C), 48.4 (2C). ESI-MS m/z 401 (M+H)+.
Anal. calcd. for C19H17ClN4O2S: C, 56.93; H, 4.27; N, 13.98;
Found: C, 56.90; H, 4.29; N, 13.95.
4-(6-Chloro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(4-
chlorophenyl)piperazine-1-carboxamide (14)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol) and 4-chlorophenyl
isocyanate (0.05 g, 0.35 mmol) to afford 14 (0.05 g, 36.89%) as
white solid. M.p: 222–224 C. 1H NMR (DMSO-d6): dH 10.51 (b,
1H), 8.56–7.42 (m, 7H), 3.14–1.86 (m, 8H). 13C NMR (DMSO-d6):
dC 167.6, 159.2, 155.4, 138.8, 137.2, 135.5, 134.2, 133.5, 131.4,
131.1, 130.5, 129.7 (2C), 120.6 (2C), 51.4 (2C), 48.2 (2C). ESI-MS
m/z 436 (M+H)+. Anal. calcd. for C19H16Cl2N4O2S: C, 52.42; H,
3.70; N, 12.87; Found: C, 52.43; H, 3.68; N, 12.89.
4-(6-Chloro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(p-
tolyl)piperazine-1-carboxamide (15)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol) and p-tolylisocyanate (0.04 g,
0.35 mmol) to afford 15 (0.06 g, 44.82%) as white solid. M.p:
197–199 C. 1H NMR (DMSO-d6): dH 10.49 (b, 1H), 8.51–7.42 (m,
7H), 3.14–1.84 (m, 8H), 2.34 (s, 3H). 13C NMR (DMSO-d6): dC
167.4, 159.7, 155.1, 138.7, 136.2, 135.5, 134.3, 131.5, 131.3,
130.1, 129.5 (2C), 121.7 (2C), 51.5 (2C), 48.4 (2C), 21.4. ESI-MS
m/z 415 (M+H)+. Anal. calcd. for C20H19ClN4O2S: C, 57.90; H,
4.62; N, 13.50; Found: C, 57.89; H, 4.59; N, 13.52.
4-(6-Chloro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(4-
nitrophenyl)piperazine-1-carboxamide (16)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol) and 4-nitrophenyl isocyanate
(0.05 g, 0.35 mmol) to afford 16 (0.08 g, 51.82%) as white solid.
M.p: 215–217 C. 1H NMR (DMSO-d6): dH 10.52 (b, 1H), 8.53–7.47
(m, 7H), 3.15–1.81 (m, 8H). 13C NMR (DMSO-d6): dC 167.7, 159.3,
155.2, 145.7, 143.2, 138.5, 135.3, 134.5, 131.3, 131.1, 130.5, 124.3
(2C), 119.8 (2C), 51.5 (2C), 48.6 (2C). ESI-MS m/z 446 (M+H)+.
Anal. calcd. for C19H16ClN5O4S: C, 51.18; H, 3.62; N, 15.71;
Found: C, 51.19; H, 3.65; N, 15.74.
General procedure for the synthesis of 4-(6-substituted-4-oxo-
4H-benzo[e][1,3]thiazin-2-yl)-N-arylpiperazine-1-
carbothioamide derivatives (17–28)
To a cooled solution of 6-substituted-2-(piperazin-1-yl)-4H-
benzo[e][1,3]thiazin-4-one (1 mmol) in anhydrous DCM
(2 ml) was added corresponding isothiocyanate (1 mmol), tri-
ethylamine (1 mmol) and stirred the reaction mixture at room
temperature for 12 h (monitored by TLC and LCMS for com-
pletion), and solvent evaporated under reduced pressure.The residue was further diluted with water (30 ml) and ethyl
acetate (50 ml) and the layers were separated. The organic
layer was dried over anhydrous sodium sulphate and evapo-
rated under reduced pressure. The residue was purified by sil-
ica gel column chromatography using hexane: ethyl acetate
as eluent to give the corresponding thiourea derivative (17–
28) in good yield.
4-(6-Nitro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-
phenylpiperazine-1-carbothioamide (17)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol) and phenyl isothiocyanate
(0.04 g, 0.34 mmol) to afford 17 (0.06 g, 46.50%) as yellow solid.
M.p: 221–223 C. 1H NMR (DMSO-d6): dH 9.97 (b, 1H), 8.52–7.71
(m, 8H), 3.06–1.84 (m, 8H). 13C NMR (DMSO-d6): dC 181.6,
167.5, 159.2, 145.2, 143.7, 138.2, 138.1, 130.3, 129.3 (2C), 128.4,
128.1 (2C), 126.5 (2C), 123.3, 56.7 (2C), 48.5 (2C). ESI-MS m/z
428 (M+H)+. Anal. calcd. for C19H17N5O3S2: C, 53.38; H, 4.01;
N, 16.38; Found: C, 53.40; H, 4.02; N, 16.37.
N-(4-Chlorophenyl)-4-(6-nitro-4-oxo-4H-
benzo[e][1,3]thiazin-2-yl)piperazine-1-carbothioamide (18)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one 4a) (0.1 g, 0.34 mmol) and 4-Chlorophenyl
isothiocyanate (0.05 g, 0.34 mmol) to afford 18 (0.07 g,
45.56%) as yellow solid. M.p: 189–191 C. 1H NMR (DMSO-d6):
dH 9.95 (b, 1H), 8.55–7.73 (m, 7H), 3.04–1.86 (m, 8H).
13C NMR
(DMSO-d6): dC 181.4, 167.6, 159.4, 145.7, 143.2, 138.4, 136.1,
133.3, 131.3 (2C), 130.4, 129.1 (2C), 128.5, 123.4, 56.6 (2C), 48.8
(2C). ESI-MS m/z 462 (M+H)+. Anal. calcd. for C19H16ClN5O3S2:
C, 49.40; H, 3.49; N, 15.16; Found: C, 49.43; H, 3.51; N, 15.19.
4-(6-Nitro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(p-
tolyl)piperazine-1-carbothioamide (19)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol) and p-tolyl isothiocyanate
(0.05 g, 0.34 mmol) to afford 19 (0.07 g, 48.33%) as yellow solid.
M.p: 186–188 C. 1H NMR (DMSO-d6): dH 9.93 (b, 1H), 8.58–7.81
(m, 7H), 3.07–1.88 (m, 8H), 2.36 (s, 3H). 13C NMR (DMSO-d6):
dC 181.3, 167.5, 159.8, 145.6, 143.1, 138.4, 137.1, 135.3, 130.3,
129.4 (2C), 128.1, 126.5 (2C), 123.5, 56.8 (2C), 48.3 (2C), 21.4.
ESI-MS m/z 442 (M+H)+. Anal. calcd. for C20H19N5O3S2: C,
54.41; H, 4.34; N, 15.86; Found: C, 54.39; H, 4.35; N, 15.89.
4-(6-Nitro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(4-
nitrophenyl)piperazine-1 carbothioamide (20)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol) and 4-nitrophenyl
isothiocyanate (0.06 g, 0.34 mmol) to afford 20 (0.04 g,
26.60%) as yellow solid. M.p: 192–194 C. 1H NMR (DMSO-d6):
dH 9.95 (b, 1H), 8.61–7.42 (m, 7H), 3.08–1.81 (m, 8H).
13C NMR
(DMSO-d6): dC 181.5, 167.3, 159.5, 145.8, 144.6, 143.4, 143.1,
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(2C). ESI-MS m/z 473 (M+H)+. Anal. calcd. for C19H16N6O5S2:
C, 48.30; H, 3.41; N, 17.79; Found: C, 48.33; H, 3.45; N, 17.80.
4-(4-Oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-yl)-
N-phenylpiperazine-1-carbothioamide (21)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol) and phenyl
isothiocyanate (0.04 g, 0.31 mmol) to afford 21 (0.05 g,
40.58%) as white solid. M.p: 179–181 C. 1H NMR (DMSO-d6):
dH 9.97 (b, 1H), 8.62–7.45 (m, 8H), 3.10–1.85 (m, 8H).
13C NMR
(DMSO-d6): dC 181.1, 167.9, 159.6, 140.8, 138.6, 137.4, 131.6,
130.3, 129.2 (2C), 128.4, 128.2, 126.2 (3C), 123.5, 56.7 (2C), 48.2
(2C). ESI-MS m/z 451 (M+H)+. Anal. calcd. for C20H17F3N4OS2:
C, 53.32; H, 3.80; N, 12.44; Found: C, 55.29; H, 3.91; N, 12.42.
N-(4-Chlorophenyl)-4-(4-oxo-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-2-yl)piperazine-1-carbothioamide (22)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol) and 4-
chlorophenyl isothiocyanate (0.05 g, 0.31 mmol) to afford 22
(0.06 g, 40.29%) as white solid. M.p: 193–195 C. 1H NMR
(DMSO-d6): dH 9.94 (b, 1H), 8.63–7.41 (m, 7H), 3.12–1.88 (m,
8H). 13C NMR (DMSO-d6): dC 181.8, 167.7, 159.4, 140.5, 137.6,
136.4, 133.6, 131.3, 131.2 (2C), 130.4, 129.2 (2C), 128.2, 126.5,
123.6, 56.8 (2C), 48.6 (2C). ESI-MS m/z 485 (M+H)+. Anal. calcd.
for C20H16ClF3N4OS2: C, 49.53; H, 3.33; N, 11.55; Found: C, 49.51;
H, 3.35; N, 11.54.
4-(4-Oxo-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-2-yl)-
N-(p-tolyl)piperazine-1-carbothioamide (23)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol) and p-tolyl
isothiocyanate (0.04 g, 0.31 mmol) to afford 23 (0.06 g,
45.46%) as white solid. M.p: 183–185 C. 1H NMR (DMSO-d6):
dH 9.91 (b, 1H), 8.59–7.63 (m, 7H), 3.15–1.85 (m, 8H), 2.35 (s,
3H). 13C NMR (DMSO-d6): dC 181.5, 167.1, 159.9, 140.2, 137.4,
137.2, 135.4, 131.6, 130.3, 129.2 (2C), 128.4, 126.5, 126.2 (2C),
123.5, 56.4 (2C), 48.2 (2C), 21.4. ESI-MS m/z 465 (M+H)+. Anal.
calcd. for C21H19F3N4OS2: C, 54.30; H, 4.12; N, 12.06; Found: C,
54.32; H, 4.16; N, 12.07.
N-(4-Nitrophenyl)-4-(4-oxo-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-2-yl)piperazine-1-carbothioamide (24)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol) and 4-
nitrophenyl isothiocyanate (0.05 g, 0.31 mmol) to afford 24
(0.08 g, 52.16%) as white solid. M.p: 192–194 C. 1H NMR
(DMSO-d6): dH 9.98 (b, 1H), 8.62–7.61 (m, 7H), 3.11–1.82 (m,
8H). 13C NMR (DMSO-d6): dC 181.1, 167.3, 159.4, 144.2, 143.4,
140.2, 137.4, 131.6, 130.3, 128.2, 126.4, 124.5 (2C), 124.2 (2C),
123.7, 56.3 (2C), 48.7 (2C). ESI-MS m/z 496 (M+H)+. Anal. calcd.for C20H16F3N5O3S2: C, 48.48; H, 3.25; N, 14.13; Found: C, 48.49;
H, 3.22; N, 14.17.4-(6-Chloro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-
phenylpiperazine-1-carbothioamide (25)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol) and phenyl isothiocyanate
(0.04 g, 0.35 mmol) to afford 25 (0.05 g, 34.47%) as white solid.
M.p: 199–201 C. 1H NMR (DMSO-d6): dH 9.92 (b, 1H), 8.58–7.66
(m, 8H), 3.14–1.85 (m, 8H). 13C NMR (DMSO-d6): dC 181.5,
167.5, 159.4, 138.6, 138.4, 135.2, 134.4, 131.6, 131.2, 130.2,
129.4 (2C), 128.5, 126.6 (2C), 56.3 (2C), 48.6 (2C). ESI-MS m/z
417 (M+H)+. Anal. calcd. for C19H17ClN4OS2: C, 54.73; H, 4.11;
N, 13.44; Found: C, 54.75; H, 4.14; N, 13.42.4-(6-Chloro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(4-
chlorophenyl)piperazine-1-carbothioamide (26)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol) and 4-chlorophenyl
isothiocyanate (0.05 g, 0.35 mmol) to afford 26 (0.03 g,
24.34%) as white solid. M.p: 206–208 C. 1H NMR (DMSO-d6):
dH 9.89 (b, 1H), 8.53–7.74 (m, 7H), 3.09–1.89 (m, 8H).
13C NMR
(DMSO-d6): dC 181.1, 167.4, 159.8, 138.9, 136.4, 135.5, 134.7,
133.6, 131.4, 131.2, 131.1 (2C), 130.4, 129.5 (2C), 56.5 (2C), 48.5
(2C). ESI-MS m/z 452 (M+H)+. Anal. calcd. for C19H16Cl2N4OS2:
C, 50.56; H, 3.57; N, 12.41; Found: C, 50.57; H, 3.59; N, 12.39.4-(6-Chloro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(p-
tolyl)piperazine-1-carbothioamide (27)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol) and p-tolyl isothiocyanate
(0.05 g, 0.35 mmol) to afford 27 (0.07 g, 47.73%) as white solid.
M.p: 221–223 C. 1H NMR (DMSO-d6): dH 9.91 (b, 1H), 8.54–7.71
(m, 7H), 3.05–1.92 (m, 8H), 2.36 (s, 3H). 13C NMR (DMSO-d6):
dC 181.7, 167.5, 159.1, 138.2, 137.4, 135.5, 135.3, 134.6, 131.4,
131.2, 130.3, 129.4 (2C), 126.5 (2C), 56.3 (2C), 48.9 (2C), 21.4.
ESI-MS m/z 431 (M+H)+. Anal. calcd. for C20H19ClN4OS2: C,
55.74; H, 4.44; N, 13.00; Found: C, 55.73; H, 4.45; N, 13.03.
4-(6-Chloro-4-oxo-4H-benzo[e][1,3]thiazin-2-yl)-N-(4-
nitrophenyl)piperazine-1-carbothioamide (28)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol) and 4-nitrophenyl
isothiocyanate (0.06 g, 0.35 mmol) to afford 28 (0.05 g,
31.72%) as white solid. M.p: 227–229 C. 1H NMR (DMSO-d6):
dH 9.91 (b, 1H), 8.61–7.74 (m, 7H), 3.08–1.91 (m, 8H), 2.36.
13C
NMR (DMSO-d6): dC 181.8, 167.1, 159.2, 144.2, 143.4, 138.5,
135.7, 134.4, 131.4, 131.3, 130.5, 124.4 (2C), 124.1 (2C), 56.5
(2C), 48.7 (2C). ESI-MS m/z 462 (M+H)+. Anal. calcd. for
C19H16ClN5O3S2: C, 49.40; H, 3.49; N, 15.16; Found: C, 49.44;
H, 3.52; N, 15.13.
110 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 1 0 4 –1 1 5General procedure for the synthesis of 2-(4-benzylpiperazin-1-
yl)-6-substituted-4H-benzo[e][1,3]thiazin-4-one derivatives
(29–40)
To a cooled solution of 6-substituted-2-(piperazin-1-yl)-4H-
benzo[e][1,3]thiazin-4-one (1 mmol) in methanol (2 ml) was
added aldehyde (1 mmol) and sodium cyanoborohydride
(1 mmol) and stirred the reaction mixture at room tempera-
ture for 12 h (monitored by TLC and LCMS for completion),
and solvent evaporated under reduced pressure. The residue
was further diluted with water (30 ml) and ethyl acetate
(50 ml) and the layers were separated. The organic layer was
dried over anhydrous sodium sulphate and evaporated under
reduced pressure. The residue was purified by silica gel col-
umn chromatography using hexane: ethyl acetate as eluent
to give the corresponding final derivative (29–40) in good
yield.2-(4-Benzylpiperazin-1-yl)-6-nitro-4H-benzo[e][1,3]thiazin-4-
one (29)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol), benzaldehyde (0.03 g,
0.34 mmol) and sodium cyanoborohydride (0.02 g, 0.34 mmol)
to afford 29 (0.04 g, 35.16%) as yellow solid. M.p: 189–191 C. 1H
NMR (DMSO-d6):): dH 8.52–7.49 (m, 8H), 3.51 (s, 2H), 3.12–1.78
(m, 8H). 13C NMR (DMSO-d6): dC 167.4, 159.4, 145.2, 143.8,
138.5, 138.3, 130.4, 128.6, 128.4 (2C), 128.2 (2C), 127.5, 123.1,
64.5, 54.3 (2C), 49.6 (2C). ESI-MS m/z 383 (M+H)+. Anal. calcd.
for C19H18N4O3S: C, 59.67; H, 4.74; N, 14.65; Found: C, 59.66;
H, 4.71; N, 14.67.2-(4-(4-Chlorobenzyl)piperazin-1-yl)-6-nitro-4H-
benzo[e][1,3]thiazin-4-one (30)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol) 4-chlorobenzaldehyde
(0.04 g, 0.34 mmol) and sodium cyanoborohydride (0.02 g,
0.34 mmol) to afford 30 (0.06 g, 46.28%) as yellow solid. M.p:
204–206 C. 1H NMR (DMSO-d6): dH 8.53–7.47 (m, 7H), 3.54 (s,
2H), 3.14–1.80 (m, 8H). 13C NMR (DMSO-d6): dC 167.5, 159.6,
145.4, 143.7, 138.5, 136.7, 132.6, 131.4 (2C), 130.6, 128.4, 128.2
(2C), 123.7, 64.5, 54.4 (2C), 49.5 (2C). ESI-MS m/z 417 (M+H)+.
Anal. calcd. for C19H17ClN4O3S: C, 54.74; H, 4.11; N, 13.44;
Found: C, 54.72; H, 4.15; N, 13.47.2-(4-(4-Methylbenzyl)piperazin-1-yl)-6-nitro-4H-
benzo[e][1,3]thiazin-4-oneone (31)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol), 4-tolualdehyde (0.04 g,
0.34 mmol) and sodium cyanoborohydride (0.02 g, 0.34 mmol)
to afford 31 (0.05 g, 39.08%) as yellow solid. M.p: 217–219 C. 1H
NMR (DMSO-d6): dH 8.55–7.44 (m, 7H), 3.54 (s, 2H), 3.12–1.78 (m,
8H), 2.98 (s, 3H). 13C NMR (DMSO-d6): dC 167.5, 159.6, 145.4,
143.7, 138.5, 136.7, 135.6, 130.6, 130.4 (2C), 128.6, 128.5 (2C),123.2, 64.5, 54.4 (2C), 49.5 (2C), 21.4. ESI-MS m/z 397 (M+H)+.
Anal. calcd. for C20H20N4O3S: C, 60.59; H, 5.08; N, 14.13;
Found: C, 60.62; H, 5.10; N, 14.11.
6-Nitro-2-(4-(4-nitrobenzyl)piperazin-1-yl)-4H-
benzo[e][1,3]thiazin-4-one (32)
The compound was synthesized according to the general pro-
cedure using 6-nitro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4a) (0.1 g, 0.34 mmol), 4-Nitro benzaldehyde
(0.05 g, 0.34 mmol) and sodium cyanoborohydride (0.02 g,
0.34 mmol) to afford 32 (0.05 g, 39.98%) as yellow solid. M.p:
201–203 C. 1H NMR (DMSO-d6): dH 8.58–7.47 (m, 7H), 3.56 (s,
2H), 3.11–1.79 (m, 8H). 13C NMR (DMSO-d6): dC 167.4, 159.3,
146.5, 145.5, 144.7, 143.6, 138.4, 130.6, 129.4 (2C), 128.4, 123.5,
123.2 (2C), 64.6, 54.2 (2C), 49.6 (2C). ESI-MS m/z 428 (M+H)+.
Anal. calcd. for C19H17N5O5S: C, 53.39; H, 4.01; N, 16.38;
Found: C, 53.37; H, 4.02; N, 16.36.
2-(4-Benzylpiperazin-1-yl)-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-4-one (33)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol), benzaldehyde
(0.03 g, 0.31 mmol) and sodium cyanoborohydride (0.02 g,
0.31 mmol) to afford 33 (0.08 g, 64.52%) as white solid. M.p:
186–188 C. 1H NMR (DMSO-d6): dH 8.60–7.52 (m, 8H), 3.54 (s,
2H), 3.14–1.82 (m, 8H). 13C NMR (DMSO-d6): dC 167.2, 159.5,
140.5, 138.4, 137.5, 131.7, 130.6, 128.7 (2C), 128.4 (2C), 128.2,
127.4, 126.2, 123.2, 64.4, 54.8 (2C), 49.7 (2C). ESI-MS m/z 406
(M+H)+. Anal. calcd. for C20H18F3N3OS: C, 59.25; H, 4.47; N,
10.36; Found: C, 59.24; H, 4.49; N, 10.35.
2-(4-(4-Chlorobenzyl)piperazin-1-yl)-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-4-one (34)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol), 4-chloro
benzaldehyde (0.04 g, 0.31 mmol) and sodium cyanoborohy-
dride (0.02 g, 0.31 mmol) to afford 34 (0.08 g, 63.05%) as white
solid. M.p: 182–184 C. 1H NMR (DMSO-d6): dH 8.59–7.51 (m,
7H), 3.55 (s, 2H), 3.16–1.80 (m, 8H). 13C NMR (DMSO-d6): dC
167.5, 159.5, 140.5, 137.4, 136.5, 132.7, 131.6 (3C), 130.4, 128.5
(2C), 128.2, 126.2, 123.2, 64.5, 54.7 (2C), 49.6 (2C). ESI-MS m/z
440 (M+H)+. Anal. calcd. for C20H17ClF3N3OS: C, 54.61; H,
3.90; N, 9.55; Found: C, 54.60; H, 3.88; N, 9.56.
2-(4-(4-Methylbenzyl)piperazin-1-yl)-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-4-one (35)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol), 4-tolualdehyde
(0.03 g, 0.31 mmol) and sodium cyanoborohydride (0.02 g,
0.31 mmol) to afford 35 (0.06 g, 48.09%) as white solid. M.p:
193–195 C. 1H NMR (DMSO-d6): dH 8.61–7.54 (m, 7H), 3.52 (s,
2H), 3.14–1.83 (m, 8H), 2.98 (s, 3H). 13C NMR (DMSO-d6): dC
167.5, 159.3, 140.4, 137.4, 136.1, 135.7, 131.5, 130.4, 130.1 (2C),
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MS m/z 420 (M+H)+. Anal. calcd. for C21H20F3N3OS: C, 60.13; H,
4.81; N, 10.02; Found: C, 60.15; H, 4.79; N, 10.01.
2-(4-(4-Nitrobenzyl)piperazin-1-yl)-6-(trifluoromethyl)-4H-
benzo[e][1,3]thiazin-4-one (36)
The compound was synthesized according to the general pro-
cedure using 2-(piperazin-1-yl)-6-(trifluoromethyl)-4H-ben-
zo[e][1,3]thiazin-4-one (4b) (0.1 g, 0.31 mmol), 4-
nitrobenzaldehyde (0.04 g, 0.31 mmol) and sodium cyanobor-
ohydride (0.02 g, 0.31 mmol) to afford 36 (0.08 g, 58.77%) as
white solid. M.p: 183–185 C. 1H NMR (DMSO-d6): dH 8.58–7.52
(m, 7H), 3.54 (s, 2H), 3.14–1.83 (m, 8H). 13C NMR (DMSO-d6):
dC 167.7, 159.3, 146.4, 144.2, 140.1, 137.7, 131.5, 130.2, 129.7
(2C), 128.4, 126.2, 123.4, 123.2 (2C), 64.5, 54.4 (2C), 49.8 (2C).
ESI-MS m/z 451 (M+H)+. Anal. calcd. for C20H17F3N4O3S: C,
53.33; H, 3.80; N, 12.44; Found: C, 53.29; H, 3.81; N, 12.43.
2-(4-Benzylpiperazin-1-yl)-6-chloro-4H-benzo[e][1,3]thiazin-
4-one (37)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol), benzaldehyde (0.03 g,
0.35 mmol) and sodium cyanoborohydride (0.02 g, 0.35 mmol)
to afford 37 (0.07 g, 54.55%) as white solid. M.p: 197–199 C. 1H
NMR (DMSO-d6): dH 8.63–7.55 (m, 8H), 3.56 (s, 2H), 3.12–1.81 (m,
8H). 13C NMR (DMSO-d6): dC 167.5, 159.2, 138.4, 138.2, 135.1,
134.7, 131.5, 131.2, 130.7, 128.4 (2C), 128.2 (2C), 127.4, 64.4,
54.6 (2C), 49.7 (2C). ESI-MS m/z 372 (M+H)+. Anal. calcd. for
C19H18ClN3OS: C, 61.36; H, 4.88; N, 11.30; Found: C, 61.33; H,
4.89; N, 11.31.
6-Chloro-2-(4-(4-chlorobenzyl)piperazin-1-yl)-4H-
benzo[e][1,3]thiazin-4-oneone (38)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol), 4-chlorobenzaldehyde
(0.05 g, 0.35 mmol) and sodium cyanoborohydride (0.02 g,
0.35 mmol) to afford 38 (0.07 g, 50.62%) as white solid. M.p:
205–207 C. 1H NMR (DMSO-d6): dH 8.60–7.54 (m, 7H), 3.55 (s,
2H), 3.11–1.82 (m, 8H). 13C NMR (DMSO-d6): dC 167.6, 159.4,
138.4, 136.2, 135.4, 134.6, 132.5, 131.6, 131.3, 131.1 (2C), 130.4,
128.4 (2C), 64.5, 54.3 (2C), 49.7 (2C). ESI-MS m/z 407 (M+H)+.
Anal. calcd. for C19H17Cl2N3OS: C, 56.16; H, 4.22; N, 10.34;
Found: C, 56.17; H, 4.25; N, 10.33.
6-Chloro-2-(4-(4-methylbenzyl)piperazin-1-yl)-4H-
benzo[e][1,3]thiazin-4-one (39)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol), 4-tolualdehyde (0.04 g,
0.35 mmol) and sodium cyanoborohydride (0.02 g, 0.35 mmol)
to afford 39 (0.06 g, 50.38%) as white solid. M.p: 211–213 C. 1H
NMR (DMSO-d6): dH 8.62–7.52 (m, 7H), 3.52 (s, 2H), 3.12–1.81 (m,
8H), 2.98 (s, 3H). 13C NMR (DMSO-d6): dC 167.5, 159.2, 138.5,
136.2, 135.4, 135.2, 134.5, 131.2, 131.1, 130.4, 130.1 (2C), 128.6(2C), 64.4, 54.6 (2C), 49.6 (2C), 21.1 (2C). ESI-MS m/z 386
(M+H)+. Anal. calcd. for C20H20ClN3OS: C, 62.25; H, 5.22; N,
10.89; Found: C, 62.25; H, 5.24; N, 10.88.
6-Chloro-2-(4-(4-nitrobenzyl)piperazin-1-yl)-4H-
benzo[e][1,3]thiazin-4-one (40)
The compound was synthesized according to the general pro-
cedure using 6-chloro-2-(piperazin-1-yl)-4H-benzo[e][1,3]thia-
zin-4-one (4c) (0.1 g, 0.35 mmol), 4-nitrobenzaldehyde (0.05 g,
0.35 mmol) and sodium cyanoborohydride (0.02 g, 0.35 mmol)
to afford 40 (0.07 g, 52.72%) as white solid. M.p: 215–217 C. 1H
NMR (DMSO-d6): dH 8.64–7.56 (m, 7H), 3.56 (s, 2H), 3.12–1.81 (m,
8H). 13C NMR (DMSO-d6): dC 167.4, 159.3, 146.5, 144.2, 138.4,
135.4, 134.9, 131.6, 131.1, 130.4, 129.8 (2C), 123.7 (2C), 64.4,
54.2 (2C), 49.4 (2C). ESI-MS m/z 417 (M+H)+. Anal. calcd. for
C19H17ClN4O3S: C, 54.74; H, 4.11; N, 13.44; Found: C, 54.76; H,
4.13; N, 13.42.Enzymology
In vitro MTB DNA supercoiling assay
Supercoiling assay involves the GyrA and GyrB subunits. The
holoenzyme performs the function of supercoiling the DNA.
The assay was performed using MTB DNA supercoiling assay
kits (Inspiralis Ltd., Norwich, UK). Briefly, the assay was per-
formed in a 30lL reaction volume for 30 min at 37 C in an
assay buffer containing 50 mM HEPES–KOH (pH 7.9), 6 mM
magnesium acetate, 4 mM dithiothreitol (DTT), 1 mM ATP,
100 mM potassium glutamate, 2 mM spermidine and
0.05 mg/mL albumin. During the assay, 1U of DNA gyrase
was incubated with 0.5 lg of relaxed pBR322 in the assay buf-
fer for 30 min. Various concentrations of the compounds were
diluted and incubated along with the reactants. The incuba-
tion time was optimized based on the interaction and activity
of the protein with the double stranded DNA. Subsequently,
the reaction was quenched by addition of an equal volume
of 30 lL of chloroform:isoamyl alcohol (24:1) and STEB buffer
[sucrose–Tris–HCl–ethylene diamine tetra-acetic acid (EDTA)–
bromophenol blue], with a brief vortex followed by cen-
trifugation [14]. Products were analyzed by electrophoresis
on 1% agarose gels after staining with ethidium bromide.
Using Image Lab TM software (Bio-Rad), the intensity of bands
was measured and analyzed to determine enzyme inhibition
by relative band intensity comparing with the control. In this
assay too, novobiocin was set as a standard.
In vitro MTB MABA assay
Briefly, the MTB inoculum was prepared from fresh LJ med-
ium re-suspended in 7H9-S medium (7H9 broth, 0.1% casi-
tone, 0.5% glycerol, supplemented oleic acid, albumin,
dextrose, and catalase [OADC]), adjusted to a McFarland tube
No. 1, and diluted 1:20; 100 lL was used as inoculum [15]. Each
drug stock solution was thawed and diluted in 7H9-S at four-
fold the final highest concentration tested. Serial twofold
dilutions of each drug were prepared directly in a sterile 96-
well microtiter plate using 100 lL 7H9-S. A growth control
containing no antibiotic and a sterile control were also
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ter wells to avoid evaporation during the incubation. The
plate was covered, sealed in plastic bags and incubated at
37 C in normal atmosphere. After 7 days incubation, 30 lL
of alamar blue solution was added to each well, and the plate
was re-incubated overnight. A change in colour from blue
(oxidized state) to pink (reduced) indicated the growth of bac-
teria, and the MIC was defined as the lowest concentration of
drug that prevented this change in colour.In vitro cytotoxicity studies
Eukaryotic RAW 264.7 mouse macrophage cells were used to
test the cytotoxic activity of all the compounds [16]. The toxi-
city was measured by incubating the test compounds in 96CONH2
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Chemical structure of previously reported antitubercular
benzothiazinone bearing (left-hand side) derivative
PBTZ169 and MTB DNA gyrase inhibitor bearing aryl (thio)
urea right hand side chain and the inhibitor designed
through molecular hybridization.flat-bottomed well plates containing a cell count of 5 · 105
at different concentrations, with 5% CO2 and 95% O2 atmo-
sphere for 48 h at 37 C. About 4 h, before the end of incuba-
tion period 10 lL of MTT reagent (10 mgmL1) was added,
the plate was centrifuged at 1200 rcf for about 3 min to obtain
a clear supernatant, the supernatant was removed, and sub-
sequently to each well 200 lL of DMSO was added to dissolve
the formed formazan crystals [6]. The absorbance was mea-
sured at a wavelength of 560 nm on Perkin Elmer Victor X3
microplate reader against the blank after a span of 10 min.
The assay was performed in triplicates for each concentration
of drug to minimize the error rate. The cytotoxicity of each
compound was expressed as% inhibition at that particular
concentration.Results and discussion
Design and synthesis
In this paper, novel MTB DNA gyrase inhibitors were designed
by using a molecular hybridization technique. This novel
terminology in the field of drug design and development
where fusion/hybridization of two or more pharmacophoric
subunits occurs from the molecular structure of ligands/pro-
totypes was previously reported to have an inhibitory effect
against the targeted disease. This newly designed hybrid
can lead to compounds with improved affinity and efficacy
with lower side effects than the parent template compounds,
while retaining the desired characteristics of the original tem-
plate. Earlier, various literatures have explored this methodol-
ogy in designing newer analogues as potential candidate
drugs for biological evaluation. Encouraged by the previous
successful research efforts in this regard [17], it was decided
to further extend the above methodology to identify novel
starting points to design inhibitors for ATPase domain of
mycobacterial gyrase (see Fig. 1).S
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pounds has been delineated in Scheme 1. Synthesis of the
compounds started with conversion of commercially avail-
able substituted 2-chlorobenzoic acids into corresponding
2-chlorobenzoyl chlorides by DMF-catalyzed treatment in
the presence of oxalyl chloride in dichloromethane. The
obtained 2-chlorobenzoyl chlorides were converted into
corresponding amide intermediate by drop wise addition
of 25% aqueous ammonia at 20 C. The amide inter-
mediates were further treated with carbon disulphide,
methyl iodide and sodium hydroxide in DMSO to affordTable 1 – Enzyme inhibitory effect of synthesized compounds a
S
NO N
R1
N
S
NO N
R1
N
5-16 17
N
H
O
R2
Comp R1 R2 Supercoiling assay (IC50
5 NO2 H 16.84 ± 0.27
6 NO2 Cl 23.71 ± 0.21
7 NO2 CH3 9.62 ± 0.17
8 NO2 NO2 9.11 ± 0.34
9 CF3 H 10.95 ± 0.22
10 CF3 Cl 10.52 ± 0.26
11 CF3 CH3 5.26 ± 0.35
12 CF3 NO2 26.45 ± 0.31
13 Cl H 17.51 ± 0.28
14 Cl Cl 10.46 ± 0.24
15 Cl CH3 2.62 ± 0.13
16 Cl NO2 4.61 ± 0.18
17 NO2 H 0.77 ± 0.06
18 NO2 Cl 0.51 ± 0.16
19 NO2 CH3 0.82 ± 0.03
20 NO2 NO2 2.59 ± 0.14
21 CF3 H 0.83 ± 0.18
22 CF3 Cl 4.23 ± 0.33
23 CF3 CH3 4.51 ± 0.26
24 CF3 NO2 2.16 ± 0.11
25 Cl H 10.93 ± 0.34
26 Cl Cl 6.86 ± 0.24
27 Cl CH3 11.56 ± 0.18
28 Cl NO2 6.23 ± 0.15
29 NO2 H 3.21 ± 0.32
30 NO2 Cl 3.68 ± 0.19
31 NO2 CH3 8.93 ± 0.24
32 NO2 NO2 4.21 ± 0.33
33 CF3 H 11.52 ± 0.17
34 CF3 Cl 3.86 ± 0.13
35 CF3 CH3 11.63 ± 0.98
36 CF3 NO2 4.55 ± 0.31
37 Cl H 17.64 ± 0.66
38 Cl Cl 12.11 ± 0.42
39 Cl CH3 21.54 ± 0.59
40 Cl NO2 7.33 ± 0.36
Novobiocin 0.068 ± 0.07the thioalkylated products, which upon treatment with
1-Boc-piperazine in ethanol followed by deprotection using
trifluoroacetic acid gave the scaffolds in good yield. The
final library was then assembled by treating the obtained
scaffolds with the desired isocyanates/isothiocyanates and
aldehydes to afford compound 5–40 in excellent yields. A
series of 36 derivatives were prepared using the above
method for the present study; both analytical and spectral
data (1H NMR, 13C NMR, and mass spectra) of all the syn-
thesized compounds were in full agreement with the pro-
posed structures.nd their antitubercular activity.
S
NO N
R1
N
-28 29-40
N
H
S
R2
R2
) (lM) MIC (lM) Cytotoxicity in RAW 264.7 cells
30.38 ND
28.03 ND
14.68 16.24
13.67 15.23
19.18 ND
13.32 10.24
11.54 7.56
52.14 ND
15.59 16.52
17.91 2.56
6.02 5.14
5.24 3.56
1.82 3.25
4.41 1.81
2.83 4.22
5.29 2.21
4.62 6.48
8.59 3.15
9.54 16.45
5.04 5.48
11.22 2.35
6.92 25.64
14.5 2.48
13.52 1.45
4.08 5.41
5.99 1.56
15.76 26.54
7.31 21.35
15.41 ND
6.31 8.45
16.73 18.56
5.19 14.56
33.61 ND
15.38 5.36
24.25 2.36
14.99 5.48
>200 7.56
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The supercoiling of the DNA is required to maintain the
bacteria in a viable state. All the 36 inhibitors synthesized
were screened for their effectivity to inhibit the supercoiling
activity of the DNA gyrase. Among the tested compounds,
(18) emerged at sub micro molar inhibitory profile. The
nitro group at the R1 position and the chloro group at the
R2 positions were favourable for the effective inhibition
of the benzothiazinone derivative with an IC50 of
0.51 ± 0.16 lM. Compounds synthesized had various strong
electron withdrawing substitutions like nitro, trifluoro and
weak chloro groups, at the substituted R1 position while
the R2 was substituted with hydrogen, chloro, methyl and
nitro groups. Among the twelve R1 substituted nitro groups,
ten molecules showed an IC50 of less than 10 lM, only com-
pound (5) and (6) had lower inhibition rates highlighting the
importance of the nitro group substitution at this position.
All the enzyme studies were carried out in the presence
of standard drug novobiocin with an IC50 was 68 nM.
Among the 36 compounds subjected to inhibitory assays,
compound (18) N-(4-chlorophenyl)-4-(6-nitro-4-oxo-4H-ben-
zo[e][1,3]thiazin-2-yl)piperazine-1-carbothioamide was the
most potent analogue. Four compounds (17, 18, 19 and
21) showed nano molar range inhibitions in the supercoil-
ing assay as shown in Table 1. Furthermore, all the com-
pounds were then subjected to a number of tertiary
screens in order to assess their in vitro anti-tubercular
potency and cell cytotoxicity insights. Moreover, one of
the major hurdles in target-based drug discovery is the lack
of translation of the drug potency and selectivity observed
at the enzyme level to that of mycobacterial cidality. In
order to re-ascertain the compounds efficiencies, molecules
were first subjected to whole cell screening against MTB
H37Rv strain using the broth dilution method [15] with
compound concentrations ranging from 50 to 1.56 lg/mL
in triplicates. Fifteen compounds showed an MIC of less
than 10 lM concentration highlighting the importance of
this series in the bactericidal activity. Compounds (17),
(19) and (21) had MIC less than 5 lM. The most active com-
pound (18) in the DNA gyrase enzyme assay showed
4.41 lM MIC probably due to the cell efflux pumps, while
the compound (17) had a better MIC than (18) owing to
its neutral R2 positions H group. The standard compound
novobiocin which showed excellent activity in MTB DNA
gyrase was completely inactive in the log phase culture of
MTB. None of the compounds were more potent than ear-
lier reported benzothiazinone derivatives [12,13]. Further,
all the synthesized compounds were further screened for
their in vitro cytotoxicity’s in the RAW 264.7 mouse macro-
phage cell lines [16], since the predominant host cells for
MTB are the lung macrophages. The concentration was
set at 100 lM and the assay was done by the (4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Compounds with an MIC of less than 15 lM
alone were tested for the cytotoxicity studies. All those
compounds tested showed below 25% cell toxicities. The
most active compound (18) had 1.81% inhibition compara-
tively much less than the standard novobiocin. All the
results are represented in Table 1 [18,19].Conclusion
In the continuous efforts to discover novel antimicrobial com-
pounds with anti-gyrase activity, this study has described the
discovery of benzothiazinone as a gyrase inhibitor with
potent MTB MIC and inhibitory profiles of the gyrase enzyme
with a well correlated structural activity relationship and less
cytotoxic effect. Furthermore, it is believed that this class of
compounds has further potential to be developed as an
anti-TB drug candidate.Conflict of interest
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